Opening the Door for Novel Therapies in Triple-Negative Breast Cancer
Jennifer Logan, MD, MPH
Published: Tuesday, Mar 31, 2020
Debu Tripathy, MD
A wave of change has taken hold of the treatment landscape for triple-negative breast cancer (TNBC). Recent successes demonstrated in clinical trial data have led to the approval of new immunotherapy and targeted agents, thanks in part to the molecular classification of TNBC.
... to read the full story